Literature DB >> 11337165

Formulation of a reservoir-type testosterone transdermal delivery system.

M K Kim1, H Zhao, C H Lee, D D Kim.   

Abstract

A reservoir-type transdermal delivery system of testosterone (TS) was developed using an ethanol/water (70:30) cosolvent system as the vehicle. The maximum permeation rate achieved by 70% (v/v) of ethanol was further increased from 2.69 to 47.83 microg/cm(2)/h with the addition of 1.0% dodecylamine as the skin permeation enhancer. The permeation rate of TS through the ethylene vinyl acetate (EVA) membrane was observed to increase as the vinyl acetate content in the copolymer increased. Addition of 1.0% (w/w) gelling agent, hydroxypropyl methlycellulose (HPMC), in the reservoir formulation resulted in desirable rheological properties with an insignificant effect on the skin permeation rate of TS. Thus, a new transdermal delivery system for TS was formulated using EVA membrane coated with a pressure-sensitive adhesive (Duro-Tak 87-2510) and HPMC as a gelling agent. This experimental patch showed comparable plasma concentration profiles in the in vivo study when compared with a commercial product, Androderm(R). Moreover, the results suggested the possibility of further enhancing the permeation rate of TS by controlling the composition of the reservoir formulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11337165     DOI: 10.1016/s0378-5173(01)00631-7

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

Review 1.  Testosterone hormone replacement therapy: state-of-the-art and emerging technologies.

Authors:  Marie-Laure Leichtnam; Hervé Rolland; Patrick Wüthrich; Richard H Guy
Journal:  Pharm Res       Date:  2006-06-09       Impact factor: 4.200

Review 2.  Delivering non-hormonal contraceptives to men: advances and obstacles.

Authors:  Dolores D Mruk; C Yan Cheng
Journal:  Trends Biotechnol       Date:  2008-01-11       Impact factor: 19.536

3.  Preclinical evaluation of drug in adhesive type ondansetron loaded transdermal therapeutic systems.

Authors:  Kalpana Swain; Satyanarayan Pattnaik; Nilufa Yeasmin; Subrata Mallick
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-06-29       Impact factor: 2.441

4.  Male osteoporosis and androgenic therapy: from testosterone to SARMs.

Authors:  Antonio Cilotti; Alberto Falchetti
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

5.  In vitro and in vivo evaluation of a novel testosterone transdermal delivery system (TTDS) using palm oil base.

Authors:  Didi Erwandi Mohamad Haron; Zamri Chik; Mohamed Ibrahm Noordin; Zahurin Mohamed
Journal:  Iran J Basic Med Sci       Date:  2015-12       Impact factor: 2.699

6.  Design, Development, and Optimization of Dexibuprofen Microemulsion Based Transdermal Reservoir Patches for Controlled Drug Delivery.

Authors:  Fatima Ramzan Ali; Muhammad Harris Shoaib; Rabia Ismail Yousuf; Syed Abid Ali; Muhammad Suleman Imtiaz; Lubna Bashir; Shazia Naz
Journal:  Biomed Res Int       Date:  2017-09-27       Impact factor: 3.411

7.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.